Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 10, pp 2765–2772 | Cite as

Epstein–Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia

  • Matthew G. Varga
  • Hui Cai
  • Tim Waterboer
  • Gwen Murphy
  • Taichi Shimazu
  • Phil R. Taylor
  • You-Lin Qiao
  • Sue K. Park
  • Keun-Young Yoo
  • Sun Ha Jee
  • Eo Rin Cho
  • Jeongseon Kim
  • Christian C. Abnet
  • Shoichiro Tsugane
  • Qiuyin Cai
  • Wei Zheng
  • Michael Pawlita
  • Xiao-Ou Shu
  • Meira Epplein
Original Article
  • 115 Downloads

Abstract

Background

Epstein–Barr virus (EBV)-positive gastric cancers represent a distinct subtype of gastric cancers and account for nearly 10% of the gastric cancer burden, yet risk detection strategies for this cancer subtype are lacking.

Methods

We conducted a nested case–control study where we assayed 4 EBV antigens [viral capsid antigen (VCA), early antigen (EA), Epstein–Barr nuclear antigen (EBNA), and BZLF1-encoded replication activator protein (ZEBRA)] in either sera or plasma from 1447 gastric cancer cases and 1797 controls obtained from seven prospective cohorts representing individuals from the high gastric cancer-risk countries of China, Japan, and Korea.

Results

The prevalence of EBV sero-positivity was universal with the exception of one sero-negative individual, and the highest titers of the EBV antigens VCA (OR 0.95, 95% CI 0.78–1.17), EBNA (OR 0.88, 95% CI 0.72–1.08), EA (OR 0.97, 95% CI 0.79–1.19), and ZEBRA (OR 0.87, 95% CI 0.71–1.07) were not associated with risk of incident gastric cancer. When we stratified these data by H. pylori status, there was no change in the association.

Conclusions

Multiplex serology of the aforementioned EBV antigens in serum may not be a suitable biomarker for predicting gastric cancer risk in East Asian populations.

Keywords

Epstein–Barr virus Gastric cancer Multiplex serology 

Notes

Acknowledgments

This work was supported by the National Institute of Health and the National Cancer Institute R01CA174853 (M. Epplein) and the Molecular and Genetic Epidemiology of Cancer Fellowship R25CA160056 (X.-O. Shu, P. I. and M. G. Varga, Trainee) and the Cancer Control Education Program 2T32CA057726-26 (K. Ribisl, P. I. and M. G. Varga, Trainee). The Shanghai Men’s and Women’s studies were supported by Grants from the National Cancer Institute (R37 CA070867 and UM1 CA182910 to W. Zheng; R01 CA082729 and UM1 CA 173640 to X.-O. Shu).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

10620_2018_5154_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 15 kb)
10620_2018_5154_MOESM2_ESM.docx (16 kb)
Supplementary material 2 (DOCX 15 kb)

References

  1. 1.
    Niedobitek G, Meru N, Delecluse HJ. Epstein–Barr virus infection and human malignancies. Int J Exp Pathol. 2001;82:149–170.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRefPubMedGoogle Scholar
  3. 3.
    Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein–Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137:824–833.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Coghill AE, Hildesheim A. Epstein–Barr virus antibodies and the risk of associated malignancies: review of the literature. Am J Epidemiol. 2014;180:687–695.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Young LS, Yap LF, Murray PG. Epstein–Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016;16:789–802.CrossRefPubMedGoogle Scholar
  6. 6.
    Fuentes-Panana EM, Morales-Sanchez A. Epstein–Barr virus-associated gastric cancer and potential mechanisms of oncogenesis. Curr Cancer Drug Targets. 2016;16:1–21.Google Scholar
  7. 7.
    Saju P, Murata-Kamiya N, Hayashi T, et al. Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein–Barr virus. Nat Microbiol. 2016;1:16026.CrossRefPubMedGoogle Scholar
  8. 8.
    De Vathaire F, Sancho-Garnier H, de-The H, et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. Int J Cancer. 1988;42:176–181.CrossRefGoogle Scholar
  9. 9.
    Henle G, Henle W. Epstein–Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976;17:1–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim Y, Shin A, Gwack J, et al. Epstein–Barr virus antibody level and gastric cancer risk in Korea: a nested case-control study. Br J Cancer. 2009;101:526–529.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Koshiol J, Qiao YL, Mark SD, et al. Epstein–Barr virus serology and gastric cancer incidence and survival Br J Cancer. 2007;97:1567–1569.PubMedGoogle Scholar
  12. 12.
    Levine PH, Stemmermann G, Lennette ET, Hildesheim A, Shibata D, Nomura A. Elevated antibody titers to Epstein–Barr virus prior to the diagnosis of Epstein–Barr-virus-associated gastric adenocarcinoma. Int J Cancer. 1995;60:642–644.CrossRefPubMedGoogle Scholar
  13. 13.
    Shinkura R, Yamamoto N, Koriyama C, Shinmura Y, Eizuru Y, Tokunaga M. Epstein–Barr virus-specific antibodies in Epstein–Barr virus-positive and -negative gastric carcinoma cases in Japan. J Med Virol.. 2000;60:411–416.CrossRefPubMedGoogle Scholar
  14. 14.
    Michel A, Waterboer T, Kist M, Pawlita M. Helicobacter pylori multiplex serology. Helicobacter. 2009;14:525–535.CrossRefPubMedGoogle Scholar
  15. 15.
    Teras LR, Rollison DE, Pawlita M, et al. Epstein–Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies. Int J Cancer. 2015;136:108–116.CrossRefPubMedGoogle Scholar
  16. 16.
    Cai H, Ye F, Michel A, et al. Helicobacter pylori blood biomarker for gastric cancer risk in East Asia. Int J Epidemiol. 2016;45:774–781.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gao L, Michel A, Weck MN, Arndt V, Pawlita M, Brenner H. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res. 2009;69:6164–6170.CrossRefPubMedGoogle Scholar
  18. 18.
    Shakeri R, Malekzadeh R, Nasrollahzadeh D, et al. Multiplex H. pylori serology and risk of gastric cardia and noncardia adenocarcinomas. Cancer Res. 2015;75:4876–4883.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Gao L, Weck MN, Michel A, Pawlita M, Brenner H. Association between chronic atrophic gastritis and serum antibodies to 15 Helicobacter pylori proteins measured by multiplex serology. Cancer Res. 2009;69:2973–2980.CrossRefPubMedGoogle Scholar
  20. 20.
    Camargo MC, Murphy G, Koriyama C, et al. Determinants of Epstein–Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011;105:38–43.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Shannon-Lowe C, Rowe M. Epstein–Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. PLoS Pathog. 2011;7:e1001338.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ji MF, Wang DK, Yu YL, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer.. 2007;96:623–630.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Li S, Deng Y, Li X, Chen QP, Liao XC, Qin X. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chin Med J (Engl).. 2010;123:1201–1205.PubMedGoogle Scholar
  24. 24.
    Amieva M, Peek RM Jr. Pathobiology of Helicobacter pylori-Induced Gastric Cancer. Gastroenterology. 2016;150:64–78.CrossRefPubMedGoogle Scholar
  25. 25.
    Treece AL, Duncan DL, Tang W, et al. Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein–Barr virus-related expression patterns. Lab Investig J Tech Methods Pathol. 2016;96:661–671.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Matthew G. Varga
    • 1
    • 2
  • Hui Cai
    • 2
  • Tim Waterboer
    • 3
  • Gwen Murphy
    • 4
  • Taichi Shimazu
    • 5
  • Phil R. Taylor
    • 4
  • You-Lin Qiao
    • 6
  • Sue K. Park
    • 7
  • Keun-Young Yoo
    • 8
  • Sun Ha Jee
    • 9
  • Eo Rin Cho
    • 9
  • Jeongseon Kim
    • 10
  • Christian C. Abnet
    • 4
  • Shoichiro Tsugane
    • 5
  • Qiuyin Cai
    • 2
  • Wei Zheng
    • 2
  • Michael Pawlita
    • 3
  • Xiao-Ou Shu
    • 2
  • Meira Epplein
    • 2
    • 11
  1. 1.Department of Epidemiology, Gillings School of Global Public Health and Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer CenterVanderbilt University Medical CenterNashvilleUSA
  3. 3.Division of Molecular Diagnostics of Oncogenic Infections, Research Program in Infection, Inflammation, and CancerGerman Cancer Research Center (DFKZ)HeidelbergGermany
  4. 4.Division of Cancer Epidemiology and GeneticsNational Cancer InstituteBethesdaUSA
  5. 5.Epidemiology and Prevention GroupNational Cancer CenterTokyoJapan
  6. 6.Department of Cancer EpidemiologyChinese Academy of Medical Sciences and Peking Union Medial CollegeBeijingChina
  7. 7.Department of Biomedical Sciences, Cancer Research InstituteSeoul National University College of MedicineSeoulKorea
  8. 8.Department of Preventive MedicineSeoul National University College of MedicineSeoulKorea
  9. 9.Department of Epidemiology and Health Promotion, Institute for Health PromotionYonsei UniversitySeoulKorea
  10. 10.Division of Cancer Epidemiology and Prevention, Research InstituteNational Cancer CenterGoyangKorea
  11. 11.Department of Population Health Sciences, Duke University and Cancer Control and Population Sciences ProgramDuke Cancer InstituteDurhamUSA

Personalised recommendations